• Back function (back function scale FFbHR) [ Time Frame: once at week 8 and 26 ] [ Designated as safety issue: No ]
• visual analogue scale (0-100 mm) low back pain [ Time Frame: once after week 26 ] [ Designated as safety issue: No ]
• days with medication [ Time Frame: week 4 to 8 ] [ Designated as safety issue: No ]
• quality of life (SF-36) [ Time Frame: once at week 8 and 26 ] [ Designated as safety issue: No ]
• pain disability scale (PDI) [ Time Frame: once at week 8 and 26 ] [ Designated as safety issue: No ]
• emotional pain scale (SES) [ Time Frame: once at week 8 and 26 ] [ Designated as safety issue: No ]
• influence of patient expectancy [ Time Frame: once at week 8 and 26 ] [ Designated as safety issue: No ]
• influence of physician expectancy [ Time Frame: once at week 8 and 26 ] [ Designated as safety issue: No ]
• Responder rate 36% VAS pain intensity [ Time Frame: once at week 8 and 26 ] [ Designated as safety issue: No ]
• numbers of days with absence from work [ Time Frame: between week 4 and 8 ] [ Designated as safety issue: No ]
• days with physician visits because of low back pain [ Time Frame: between week 4 and 8 ] [ Designated as safety issue: No ]

The aim of the study is to evaluate the efficacy of Disci/Rhus toxicodendron. comp.® in patients with chronic low back pain compared to waiting list group, or placebo.

Chronic low back pain is a significant health problem in industrialized countries. Use of complementary medicine is increasing in patients with low back pain. Until now there is no evidence for the efficacy of Disci/Rhus toxicodendron. comp.® in patients with chronic low back pain.

• Drug: Disci/Rhus toxicodendron comp.®
• Drug: placebo solution

• Active Comparator: Disci/Rhus toxicodendron comp.®
• Placebo Comparator: placebo solution
• No Intervention: waiting list group

Inclusion Criteria:

• Male and female patients, 30 to 75 years
• Willingness of following the study protocol
• Clinical diagnosis of chronic low back pain
• Low back pain since at least 3 months
• Average pain intensity of at least 40 mm on VAS (0-100 mm) in the last 7 days
• In the last 4 weeks only oral NSAD and muscle relaxation treatment
• Effective oral contraception in woman
• Informed consent

Exclusion Criteria:

• Previous treatment with DISCI comp.
• Treatment with other than NSAID
• Routine use of pain drugs for other diseases
• Protrusio or prolapse of one or more intervertebral discs with neurological symptoms
• Previous spine surgery
• (Suspicious) infectious spondylopathy
• Low back pain because of malignant or infectious disease
• Other causes of back pain symptoms (e.g. M. Bechterev, M. Reiter)
• Congenital deformity of spine (without minor lordosis or kyphosis or scoliosis
• (Suspicious) osteoporosis with compression fracture
• (Suspicious) spinal stenosis
• Spondylolysis or spondylolisthesis
• Physiotherapy in the last four weeks or planed during trial
• Begin of a new treatment for low back pain
• Complementary treatment in the last four weeks or planed during trial
• Patients who are not able to cooperate in a sufficient way
• Patients with alcohol or substance abuse
• Participation in another clinical trial
• Severe chronical or acute disease which does not allow study participation
• Patients with bleeding disorders or oral anticoagulation treatment
• Pregnancy and breast feeding
• Patients with application for pension
• Patients involved in planning or coordination of the study
• Hypersensitivity against drug components